Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

NCT05166382 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

350

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Cardiovascular Diseases

Interventions

BEHAVIORAL: Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
BEHAVIORAL: Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)

Sponsor

University of Colorado, Denver

Collaborators

[object Object]